SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 29.81-4.2%Dec 5 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert S. who wrote (6690)7/15/1998 5:11:00 PM
From: Cacaito  Read Replies (2) of 17367
 
You are looking at BPI as an static molecule and working alone in the
body.

You are missing that BPI is one of the body systems to irradicate
endotoxin, for example Xoma also is workin in LBP, binds LPS but does
not regulate inflamation positively as BPI does.

Antibodies are another way of the body for stopping LPSs and Xoma has
E5 a monoclonal antibody against LPSs that works, but the FDA is still
asking for more proofs. The natural antibodies in the body do not need
FDA approval, the body makes them and they work better in combination
with BPI.

Also the white cells and machrophage comes into play or should I say
fight.

Tharos is very good providing information, and very tolerant. Maybe
he was just being funny (my view.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News